CollPlant Biotechnologies Ltd Ordinary Shares (CLGN) — 分析摘要
CollPlant Biotechnologies Ltd Ordinary Shares（CLGN）的市值为5.48百万美元，最近一年的营收同比增长了+360.4%。净利润率为-484.6%。当前市盈率为-0.5倍。
核心要点
- 营收同比变化+360.4%
- 净利润率-484.6%
- 市盈率-0.5倍
CLGN的营收增长为+360.4%，市盈率为-0.5倍。
CollPlant Biotechnologies Ltd Ordinary Shares (CLGN)
更新 — ET · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
营业利润率为 -484.3% — 严重经营亏损
净利率为 -484.6% — 亏损超过收入（可能含一次性费用）
最新报表显示自由现金流为负。
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
员工人数
39
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。